ROAD MAP

ATG symbio Spain

Cancerappy participated in the II international congress organized by ATG Symbio Spain that was held inBarcelona at the Biomedical Research Park (PRBB) on July 1 and 2, 2023.Our CEO had the opportunity to present our company and show our latest advances in the NMEs...
Read More

Bio International Convention – Boston 23

Our CEO will be attending the BIO International in Boston from June 5th to 8th. Cancerappy is dedicated to the discovery and development of new AI-based pharmaceuticals. Currently, we have a strong pipeline that validates and demonstrates our value proposition. If you...
Read More

HONG KONG INVEST – European Companies Roadshow

From 15th to 18th of May, our CEO and CMO will be attending various international events in Hong Kong introducing the latest advances of our company. They will attend Asia Summit on Global Health, Invest in Honk Kong #investHK, and different meeting with local...
Read More

MEET2WIN_23

Our CEO Luis Martín Ezama will be attending the #Meet2win23 event 11th and 12th of May, exposing the characteristics of our pipeline of new cancer drugs. We are developing first-in-class antibodies and small molecules against solid tumors.
Read More

Anglonordic 23 – London

April 20th. We are going to attend the 19th Annual Anglonordic Life Science Conference.Meet us to discuss face to face about our latest works: CA04 first-in-class monoclonal antibody, CA05 first-in-class kinase inhibitor and CA07 novel PROTAC.We can’t wait to hear...
Read More

Total funding raised Dec 2022

CancerAppy closed 2022 with €1.3M total raised.
Read More

CPP21 – InsilicoPROTACs

Cancerappy, together with UCLM, has been awarded the grant from the CCP21 program for the development of nanomedicines (nanoPROTACs), with a total budget of €757,000 and a project duration of 3 years.
Read More

AI in drug discovery

Artificial intelligence (AI) has the potential to revolutionize the drug discovery process by accelerating the identification of novel drug candidates and reducing the time and cost of drug development. In recent years, there has been a surge of interest in applying...
Read More

In the early stages, 97% of drug development fails.

In the early stages, 97% of drug development fails. The discovery and development of a new cancer drug is a long, costly, and high-risk process. The estimated time to develop a new cancer drug exceeds 10 years, costs 2 billion EUR or more, and yet only 4% of the new...
Read More

CA05 Lead Identification

We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.
Read More

2023

2022

CA05 Lead Identification

Jul 21, 2022 | ,

We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.

CA02/03 Target Identification vs NSCLC

Jan 21, 2022 | ,

CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies

2021

4YFN 2021

Jun 11, 2021 |

Cancerappy has been selected to participate in the Espacio España 4YFN 2021.  

2020

2019